

Commentary

Open Access

## Hodgkin lymphoma: flow me?

Michael W Beaty\* and Kim R Geisinger

Address: Wake Forest University School of Medicine Department of Pathology Medical Center Boulevard Winston-Salem, North Carolina 27157-1072 USA

Email: Michael W Beaty\* - mbeaty@wfubmc.edu; Kim R Geisinger - kgeis@wfubmc.edu

\* Corresponding author

Published: 08 September 2005

Received: 05 August 2005

CytoJournal 2005, 2:13 doi:10.1186/1742-6413-2-13

Accepted: 08 September 2005

This article is available from: <http://www.cytojournal.com/content/2/1/13>

© 2005 Beaty and Geisinger; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Combining fine needle aspirate cytology with flow cytometry immunophenotyping for the rapid diagnosis of lymphoproliferative lesions is commonplace practice in many institutions. Yet, a definitive diagnosis of Hodgkin lymphoma in many cases remains elusive, requiring subsequent tissue biopsy confirmation. In this issue of CytoJournal, Hernandez et al explore the potential role of using the increased CD4/CD8 T-cell ratio in lymph node fine needle aspiration specimens as a specific feature in diagnosing Hodgkin lymphoma. CD4/CD8 T-cell ratio comparisons are made with cytomorphologic diagnoses of reactive, atypical, non-Hodgkin lymphoma, and Hodgkin lymphoma cases.

Fine needle aspiration (FNA) cytomorphology in conjunction with flow cytometric (FC) immunophenotyping has become a reliable and accurate method for the diagnosis and classification of many lymphoproliferative disorders. The combined modality approach often allows for confirmation of diagnosis and subtyping of lymphoma, and in many cases obviates the necessity for a more invasive open biopsy for many patients with lymphadenopathy [1]. This is especially true in suspected cases of non-Hodgkin lymphomas (NHL). However, even with the collaborative expertise that we and others routinely employ to reach a consensus diagnosis between the cytopathologist interpreting the FNA material and the hematopathologist signing-out the FC data, the diagnosis of Hodgkin lymphoma (HL) through this method remains difficult. A FNA diagnosis of HL based purely on cytomorphology is often followed by tissue biopsy [2].

One of the major difficulties encountered with combined FNA/FC diagnosis of HL is identifying sufficient numbers of the neoplastic cells for subsequent phenotypic analysis.

In most instances, too few malignant cells for FC can be obtained from the tumors, either by FNA or biopsy material. This is due, in large part, to the cellular makeup of HL, in which the inflammatory background cells outnumber the malignant RS cells and variants by 10–100 fold. In addition, the neoplastic cells exhibit high cellular fragility, and are associated with a fibrous stroma interfering with cellular dispersion. This has led to Herculean gating efforts to isolate the RS cells and phenotype them with CD30 and CD15 [3,4]. Many other studies have looked at the components of the normal background T-lymphocyte populations present in HL, where it has long been known that there is a relative preponderance of CD4-positive T-cells, with an increased helper/cytotoxic CD4/CD8 ratio by immunohistochemistry [5-7]. We know that the RS cells and variants within the lymph node affect the surrounding cells, which results in alterations of the proportion between T and B lymphocytes and the activation of these cells, and that the relative proportion of the background lymphocytes differs depending upon the histologic subtype of the HL [8]. While the nature and

composition of the background reactive lymphocytes is helping to increase our basic understanding of the pathogenesis of the disease, it can hardly be used as a specific diagnostic feature.

In the current issue of Cytojournal, Hernandez et al compare 85 cases of combined FNA/FC lymph nodes with an increased CD4/CD8 ratio ( $>4$ ), and demonstrate no definitive quantitative differences in T-lymphocyte distribution between HL, NHL, and benign reactive lymph nodes. They report that the average CD4/CD8 ratio was essentially identical in reactive, HL, and NHL cases. This should not be surprising given the extraordinary variation in lymphocyte components in many lymphoproliferative processes. T-cell rich large B-cell lymphoma and nodular lymphocyte predominant HL are just two tumors which quickly come to mind. Both of these tumors can morphologically mimic classical HL particularly on FNA material, with only a minor population of malignant RS-like cells within a sea of reactive small lymphocytes. Phenotypic studies confirm that CD4-positive cells may exceed the CD8-positive background lymphocytes [10,11].

In a recent report by Ravoet, et al, FC was combined with lymph node biopsy to help discriminate HL, NHL, carcinoma, and reactive diagnoses [4]. Median CD4/CD8 ratios in HL were 5.0 (range 1.6–10.4), which was similar to that seen in granulomatous lymph nodes (median 3.2, range 1.5–11.8), and reactive hyperplasia (median 2.71, range 0.4–18.6). They concluded that given the large scattering of the CD4/CD8 ratios within each group, the use of the CD4/CD8 ratio is not recommended in clinical practice in order to diagnosis HL.

A quick review over the past year of lymph node FNAs performed at our institution reveals a similar wide scattering of ratios. We identified 6 cases of FNA suspected HL with a median CD4/CD8 ratio of 9.7 (range 0.3–42.5). Subsequent nodal biopsies confirmed HL in all cases. The CD4/CD8 ratio was less than 4 in half of these cases. Interestingly, one patient with an HIV-associated HL predictably had a reverse ratio, another potential pitfall. Equally important though were the six additional cases of suspected HL by FNA in which the specimens received for FC were inadequate, containing too few cells to phenotype. Thus, we rely exclusively on the morphologic features present within the FNA smears, combined with confirmatory immunohistochemical studies performed on cell block material to diagnosis HL with confidence. Otherwise, a nodal biopsy is and should be recommended [1].

Integration of clinical and biological features is one of the basic tenets of the WHO classification of lymphoproliferative disorders. While combined FNA/FC is extremely useful in the diagnosis and subclassification of some

lymphoproliferative disorders, it is not without limitation and is not the end of the diagnostic line. Until we know more about the characteristics of the T-cell milieu of HL and can point to a more specific phenotype which can be detected by FC, we must continue to rely on other ancillary tools for a definitive HL diagnosis. The work of Hernandez et al is important to remind us that an increased CD4/CD8 ratio is only one phenotypic clue present in HL, and a non-specific clue at that.

## Note

Corresponding article: Hernandez O, Oweity T, Ibrahim S: Is an Increase in CD4/CD8 T-cell ratio in lymph node fine needle aspiration helpful for diagnosing Hodgkin lymphoma? Cytojournal 2005, 2:14 [9].

## References

1. Meda BA, Buss DH, Woodruff RD, Cappellari JO, Rainer RO, Powell BL, Geisinger KR: **Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry.** *Am J Clin Pathol* 2000, **113**(5):688-99.
2. Moreland WS, Geisinger KR: **Utility and outcomes of fine-needle aspiration biopsy in Hodgkin's disease.** *Diagn Cytopathol* 2002, **26**:846-8.
3. Dunphy CH: **Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma.** *Cytometry* 2000, **42**:296-306.
4. Ravoet C, Demartin S, Gerard R, Dehon M, Peny MO, Petit B, Delannoy A, Husson B: **Contribution of flow cytometry to the diagnosis of malignant and non-malignant conditions in lymph node biopsies.** *Leukemia & Lymphoma* 2004, **45**(8):1587-93.
5. Forni M, Hofman FM, Parker JW, Lukes RJ, Talor CR: **B- and T-lymphocytes in Hodgkin's disease. An immunohistochemical study utilizing heterologous and monoclonal antibodies.** *Cancer* 1985, **55**:728-37.
6. Knowles DM: **T-lymphocyte subpopulations in B-cell derived non-Hodgkin's lymphomas and Hodgkin's disease.** *Cancer* 1984, **54**:644-651.
7. Gattringer G, Griel R, Radaszkiewicz T, Hubert H: **In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin's disease: quantity and quality of infiltration density depends on histopathological subtypes.** *Blut* 1986, **53**:49-58.
8. Pituch-Noworolska A, Drabik G, Kacinska E, Klekawka T: **Lymphocyte populations in lymph nodes in different histological types of Hodgkin's disease in children.** *Acta Haematol* 2004, **112**(3):129-35.
9. Hernandez O, Oweity T, Ibrahim S: **Is an increase in CD4/CD8 T-cell ratio in lymph node fine needle aspiration helpful for diagnosing Hodgkin lymphoma?** *Cytojournal* 2005, **2**:14.
10. Axdorph U, Powit-MacDonald A, Sjøberg J, Grimfors G, Björkholm M: **T-cell rich B-cell lymphoma – diagnostic and therapeutic aspects.** *APMIS* 2002, **110**:379-90.
11. Chan WC: **Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies.** *Semin Hematol* 1999, **36**(3):242-52.



# NextGen CelBloking™ Kits

**Frustrated with your cell blocks?  
We have a better solution!**

**Nano**

## Nano NextGen CelBloking™

Cell block kit to process single scattered cell specimens and tissue fragments of **any** cellularity.



**PATENT PENDING**



**Pack #1**



**Pack #2**

**Micro**

## Micro NextGen CelBloking™

For cellular specimens (more than 1 ml concentrated specimen with Tissuecrit more than 50%)



**PATENT PENDING**



**Pack #2**



## Co-Editors-in-Chief

Lester J. Layfield, MD, University of Missouri, USA

Vinod B. Shidham, MD, FRCPath, FIAC, Wayne State University, USA

## Assistant Editor

Nora Frisch, MD, The University of Vermont Medical Center, USA

### CytoJ Monograph Committee Co-chairs

Zubair Baloch, MD, PhD, USA

Shikha Bose, MD, USA

### CytoJ Monograph Co-editors-in-chief

R. Marshal Austin, MD, PhD, USA

Ruth Katz, MD, USA

David C. Wilbur, MD, USA

### Cytotechnology Panel

Jamie L. Covell BS, CT(ASCP), USA

Inderpreet Dhillon, MS, CT (ASCP), USA

Kalyani Naik, MS, SCT(ASCP), USA

### Hempath-Cytopath corner

#### Lead Section Editor

Ali M. Gabali, MD, PhD, USA

#### Section Editors

Chung-Che (Jeff) Chang, MD, PhD, FCAP, USA

Kedar V. Inamdar, MD, USA

Lauren Barrett Smith, MD, USA

Michael Gerard Baryerl, MD, USA

### Quiz Case Section

#### Section Editor

Tamar Giorgadze, MD, PhD, USA

#### QC Section Members

Amarpreet Bhalla, MD, USA

Linette Mejias-Badillo, MD, USA

### Associate Editors

Shikha Bose, MD

David C. Chhieng, MD, MBA, MSHI, USA

Mamatha Chivukula, MD, USA

Isam A. Eltoum, MD, MBA, USA

Rana S. Hoda, MD, FIAC, USA

Nirag Jhala, MD, MIAC, USA

Sanjay Logani, MD, MIAC, USA

Sonya Naryshkin, MD, FIAC, USA

Liron Pantanowitz, MD, USA

Husain Saleh, MD, FIAC, MBA, USA

Momin T. Siddiqui, MD, FIAC, USA

Lourdes R. Ylagan, MD, FIAC, USA

### Editorial Board Members

R. Marshall Austin, MD, PhD (USA)

Zubair Baloch, MD, PhD (USA)

George Birdsong, MD (USA)

Thomas A. Bonfiglio, MD (USA)

Shikha Bose, MD (USA)

David C. Chhieng, MD, MBA, MSHI (USA)

Mamatha Chivukula, MD (USA)

Douglas P Clark, MD (USA)

Michael B. Cohen, MD (USA)

Diane D Davey, MD (USA)

Richard M DeMay, MD (USA)

Hormoz Ehya, MD (USA)

Isam A. Eltoum, MD, MBA (USA)

James England, MD, PhD (USA)

Yener S Erozan, MD (USA)

Prabodh Gupta, MBBS,MD, FIAC (USA)

Amanda Herbert, MBBS, FRCPath (UK)

Rana S. Hoda, MD (USA)

Nirag Jhala, MD, MIAC (USA)

Kusum Kapila, MD, FIAC, FRCPath (Kuwait)

Ruth Katz, MD (USA)

Savitri Krishnamurthy, MD (USA)

Leyster Layfield, MD (USA)

Santo V Nicosia, MD (USA)

Virginia LiVolsi, MD (USA)

Britt-Marie Ljung, MD (USA)

Sanjay Logani, MD, FCAP, FASCP, MIAC (USA)

Shahla Masood, MD (USA)

Dina R Mody, MD (USA)

Sonya Naryshkin, MD, FIAC (USA)

Martha B Pitman, MD ((USA)

Liron Pantanowitz, MD (USA)

David C Wilbur, MD (USA)

Husain Saleh, MD, FIAC, MBA (USA)

Torill Sauer, MD (Norway)

Volker Schneider, MD, FIAC (Germany)

Suzanne Selvaggi, MD (USA)

Momin T. Siddiqui, MD, FIAC (USA)

Vinod B Shidham, MD, FRCPath, FIAC (USA)

Mary K Sidawy, MD (USA)

Rosemary Tambouret, MD(USA)

Jan F Silverman, MD (USA)

Philippe Vielh, MD (France)

Lourdes R. Ylagan, MD, FIAC (USA)

Kusum Verma, MBBS, MD, MIAC (India)

### CytoJournal Virtual Trainee (CVT) Corner

#### Section Editors

##### Lead Section Editor

Walid E. Khalbuss, MD, PhD, Saudi Arabia

Zubair Baloch, MD, PhD, USA

Guido Fadda, MD, Italy

Liron Pantanowitz, MD, USA

Paul Tranchida, MD, USA

#### Medicolegal Panel

Dennis R. McCoy, JD, USA

Mark S. Sidoti, Esq., USA

Michael S. Berger, JD, USA

Ken Gatter, MD, JD, USA

#### Statistical Advisor

Varghese George, PhD, USA

Global Health (Cytology)

Rajan Dewar, MD PhD, USA

#### Managing Editor

Anjani Shidham, BS, USA



## International Editorial Panel

### Argentina

Ricardo Drut, MD  
Boris Elsner, MD  
Lucrecia Illescas, MD, FIAC

### Australia

Andrew Field MB BS (Hons), FRCPA, FIAC

### Belgium

John-Paul Bogers, MD, PhD  
Alain Verhest, MD, PhD, FIAC

### Brazil

Joaõ Prolla, MD  
Vinicius Duval da Silva, MD, M.I.A.C.

### Canada

Manon Auger, MD, FRCP(C)  
Diponkar Banerjee, MBChB, FRCPC, PhD  
Terence J. Colgan, MD, FRCPC, FCAP, MIAC

### China

Terence J. Colgan, MD, FRCPC, FCAP,  
MIAC Dongge Liu, MD/PhD

### France

Beatrix Cochand-Priollet, MD, PhD, MIAC  
Jerzy Klijanienko, MD

### Germany

Magnus von Knebel Doeberitz, MD, PhD  
Ulrich Schenck, MD

### India

Deepali Jain, MD, DNB, MNAMS, FIAC  
Shubhada Kane, MD

Prakash Patil, MD, PhD

Arvind Rajwanshi, MD, MNAMS, FRCPath  
Ravi Mehrotra, MD, MNAMS

### Italy

Guido Fadda, MD  
Pio Zeppa, MD

### Japan

Toshiaki, Kawai, MD  
Robert Y. Osamura, MD

### Jordan

Maher A. Sughayer, MD

### Lebanon

Nina Salem Shabb, MD

### Netherlands

Mathilde E. Boon, MD

### Norway

Torill Sauer, MD

### Pakistan

Syed Mulazim Hussain Bukhari,  
MBBS, DCP, FCPS, PhD

### Poland

Włodzimierz T. Olszewski, MD PhD

### Portugal

Margarida Almeida, MD  
Evelina Mendonça, MD, MIAC  
Fernando Carlos de Landér Schmitt, MD

### Saudi Arabia

Mousa A. Al-Abbadi, MD, FCAP, FIAC

### Singapore

Alexander Russell Chang, MD (Otago), FRCPA  
Aileen Wee, MBBS, MRCPPath, FRCPA

### South Africa

Pam Michelow, MBBCh, MSc (Med Sci), MIAC

### Spain

Jose M. Rivera Pomar, MD  
Mercedes Santamaria Martinez, MD

### Sweden

Annika Dejmek, MD, PhD  
Karin Lindholm, MD  
Edneia Tani, MD

### Turkey

Binnur Uzmez Onal, MD, FEBP, FIAC  
Mehmet Akif Demir, MD

### UK

John H. F. Smith, MD  
Allan Wilson, MD

### Uruguay

Carmen Alvarez Santin, MD

### Vietnam

Nguyen Sao Trung, MD, PhD